UK markets closed

Spectrum Pharmaceuticals, Inc. (SPPI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0850-0.0450 (-3.98%)
As of 12:00PM EST. Market open.
Sign in to post a message.
  • d
    dcaf7
    Interesting.
    U.S. patent application number 17/278397 was filed with the patent office on 2021-11-18 for novel quinazoline egfr inhibitors. The applicant listed for this patent is Spectrum Pharmaceuticals, Inc.. Invention is credited to Prasad V. Chaturvedula.
    Abstract
    This document discloses a novel class of quinazoline EGFR inhibitors. Also disclosed are pharmaceutical compositions thereof and method for treating cancers. Disclosed herein is a novel class of quinazoline compounds which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor (EGFR).
    https://uspto.report/patent/app/20210353627
  • d
    dcaf7
    Hanmi published JP Morgan conference presentation. I like their way to demonstrate Zenith-20 results. They placed waterfall plots from four cohorts on a single slide, slide 10. Looks impressive.
    http://www.hanmi.co.kr/upfile/ces/information/INFORMATION_PRESENTATIONS/90150855/d5dbcff6-9357-4f34-baa3-66daaae9a3a7.pdf
  • d
    dcaf7
    Rolvedon is a new name for Rolontis. To me Rolontis sounds better.
    https://uspto.report/TM/97211650
  • K
    Kyelion
    https://www.mdpi.com/2072-6694/14/2/394/pdf

    EGFR Exon 20 Insertion Mutations in Sinonasal Squamous
    Cell Carcinoma
  • r
    reppeptgs
    Mission: Ongoing? Indefinite? Surely not Impossible!

    Let’s look at the numbers. SPPI continues its Quest for Stock Price Recovery, which remains elusive. This week, we set 3 new trading lows, and also tied and then set another 52-week closing low. Before Friday’s late afternoon market rally, things REALLY looked bleak. In the end, the stock lost a semi-respectable 2.59% to close at $1.13.

    The broader market and sector struggled this week due to rapid inflation and the likelihood of interest rate increases. The NAS made it two red weeks in a row to open the new year, sliding 0.28%. The loss on the year stands at 4.8%.

    The DOW was also red, but not disastrously so, falling 0.88%. For 2022, it’s now down 1.17%.

    BA was actually one of the stars of the Dow this week, as it gained 4.85%. For the young year, it has already gained 12.24%.

    My bio indexes generally did not recover from last week’s tumble. The BTK managed to salvage some dignity by closing green on the week by 1.02% (and that’s your “Highlight for the Week!”); the IBB was down 1.14%; the XBI was worst of the bunch, falling 2.49%. The conservative XLV was relatively unscathed, sliding 0.22%.

    The VXX did not benefit from the gyrations of the market, losing 2.07% by week’s end, closing at $18.43.

    Last January 14, SPPI closed at $3.59. That makes the YoY loss 68.5%, actually a slight improvement.

    Here are the daily ranges from this week:

    M 1.12*-1.20
    T 1.15-1.25
    W 1.15-1.22
    Th 1.09*-1.17
    F 1.05*-1.13

    And from last week:

    M 1.27-1.62
    T 1.41-1.58
    W 1.26-1.45
    Th 1.20*-1.31
    F 1.15*-1.26

    * Denotes a 52-week low

    Maybe the To-Do list was not a good idea. Perhaps it was too subtle. At any rate, it didn’t work.

    The problem is, the market/sector are not providing much support, and without support, a company that has no income is, well, screwed.

    Right now, time is not on our side as investors. With the market in flux, every day without news is an opportunity for new 52-week lows. As we now know in spades.

    To paraphrase a sweet old song, “what the stock, needs now, is news, sweet news”.

    Let’s listen to the original for those who remember the 70’s. Here’s a live version by Dionne Warwick that I’d never heard before now. Hope it brings a smile.

    Sarge
    Dionne Warwick - What The World Needs Now (1966)
    www.youtube.com
  • C
    Carolina
    I'm a bag holder and my average is very, very high..... however, a positive point is the 1.12. It holds as a rock, I mean Nasdaq dropped a lot and most stock just got a big red candle 10 minutes ago, but not SPPI. It seems to me it's the bottom, so I bought some shares to average down at this prices. Just check the chart.....
  • d
    dcaf7
    From BusinessKorea
    "Hanmi Pharm is expected to post consolidated 4Q21 sales of W334.5bn and OP of W32.5bn. We cut our target EV/EBITDA multiple for domestic pharmaceutical peers and lower our estimate for the company’s new drug value. In 2022, results are needed from Rolontis, Poziotinib, and Oraxol."

    "R&D performance more important than 4Q21 results

    Moving ahead, it will be important to quickly demonstrate a healthy performance on the global stage. Rolontis, a neutropenic treatment, received CRL in Aug 2020 after voluntary withdrawal of US approval in Mar 2019. Supplementary materials are being improved and should be submitted in 1H22. Now is the time when proven results are needed from Poziotinib, which was submitted for conditional approval from the FDA at end-2021, and Oraxol, which is in preparation for fast-track approval review in the UK."
    The author is an analyst of NH Investment & Securities.

    So, Rolontis and Poziotinib are very important for Hanmi. I don't like resubmission in 1H22 instead of early in 2022 as JT said.
  • S
    Sherry
    Weird stuff going on with SPPI. Four days ago, 1,311,650 shares traded A/H's at 1.16. Today, 1,311.650 shares traded A/H's at 1.13! Go figure!!
  • r
    reppeptgs
    Mission failed. The stock couldn't go 3 days without setting a new 52-week low.

    I've always liked the joke about the person who has "hit rock bottom, and then started to dig".

    It's not so funny anymore.

    Sarge
  • r
    reppeptgs
    Our mission is very clear.

    Let’s look at the numbers. Can you believe the numbers? SPPI has hit rock bottom, and now it has begun to dig. You think I’m exaggerating?

    I’ll start with last week. Last week of the year, and tax loss selling gave us its worst all the way until 12/31, with the stock hitting 52-week trading lows in 2 of the last 3 sessions.

    But the new year dawned, and SPPI came bursting out of the gates, shooting up 25% on over 5 times average volume. Clearly, the stock had been oversold! Nowhere but up from here.

    Not so fast, kid. Monday’s gain was completely erased by Wednesday’s close, and the stock wasn’t done, setting – you guessed it – new 52-week lows on Thursday and Friday. Wow. It closed the first week of 2022 with a loss of 8.66%.

    To be fair, both the broader market and the sector struggled. The NAS opened 2022 with a loss of 4.53%. FYI, it closed up 21.8% for 2021.

    The DOW played hare to the NAS tortoise, sliding 0.29%. Its 2021 closing gain was 19.5%. So the NAS won the head-to-head competition for the year.

    BA gets some credit for the supporting the Dow this week, as it gained 7.04%. For 2021, it lost 5.66%.

    My bio indexes started the year by falling on their collective faces. The BTK set the tone with a loss of 5.72%; the IBB was even worse, losing 7.91%; the XBI was worst of all, plunging 8.01%. The conservative XLV didn’t stink quite as much, falling 4.64%.

    The VXX has a rather depressing chart right now. But it gained 1.56% this week, closing at $18.82.

    Last January 8, SPPI closed at $3.74. That makes the YoY loss 68.98%. So humbling.

    Here are the daily ranges from this week:

    M 1.27-1.62
    T 1.41-1.58
    W 1.26-1.45
    Th 1.20*-1.31
    F 1.15*-1.26

    And from last week:

    M 1.39-1.52
    T 1.33-1.43
    W 1.27*-1.36
    Th 1.30-1.38
    F 1.23*-1.34

    * Denotes a 52-week low

    I’ll make this simple. Given recent market activity, there is one thing that should be at the top of everyone’s to-do list right now.

    TO DO:

    1. Stop making 52-week lows

    END OF LIST

    Sarge
  • d
    dcaf7
    Just published "A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects"
    This study was conducted in 2009 and published only now. Nice PK data. Good to have it published before approval.
  • d
    dcaf7
    JMP Securities analyst Reni Benjamin reiterated a Buy rating on Spectrum Pharmaceuticals (SPPI – Research Report) today and set a price target of $4.00. The company’s shares closed last Wednesday at $1.27.
  • d
    dcaf7
    From 8-K issued yesterday
    Pursuant to the Securities Purchase Agreement, for so long as the Investor shall beneficially own at least five percent (5%) of the total issued and outstanding shares of Common Stock, the Company shall take any and all actions reasonably necessary to nominate and appoint a designee of the Investor to serve as a member of the Board of Directors of the Company.
  • d
    dcaf7
    Follow up to Hanmi's deal.
    Hanmi said that it had changed the contract terms to support the aggressive marketing and successful commercialization of Spectrum. While the milestones received by Hanmi will decrease in the short term, the company stressed royalties to be paid after commercialization can offset this.
    "The technology transfer agreement with Spectrum has not changed in a big way, and only the details have changed," a company official said.
    Aside from the change in terms of the contract, Hanmi said that it had signed a contract to acquire 24 billion won ($20 million) worth of Spectrum stocks at $1.6 per share. Hanmi's stake in Spectrum will expand to about 10 percent with this stock acquisition.
    Hanmi explained that the background for this equity investment is to preempt the expanded future value of two innovative anticancer drugs currently under development by Spectrum and establish a strong cooperative relationship.

    출처 : KBR(http://www.koreabiomed.com)

    출처 : KBR(http://www.koreabiomed.com)

    출처 : KBR(http://www.koreabiomed.com)

    출처 : KBR(http://www.koreabiomed.com)

    http://www.koreabiomed.com/news/articleView.html?idxno=12899
    헬스케어 분야에 특화된 영자 경제신문
    헬스케어 분야에 특화된 영자 경제신문
    www.koreabiomed.com
  • d
    dcaf7
    From Korean sources, Hanmi is going to participate in JP Morgan conference next week. "Hanmi Pharmaceutical will highlight its pipeline of key novel drugs such as poziotinib and belvarafenib".
    Interesting, why didn't they mention Rolontis? Anyway, after today announced strategic investment, I guess Hanmi might consider Spectrum as an acquisition target.
  • S
    Sherry
    As of 12/31/2021, short interest dropped from 23,275,872 to 12,765,446.
  • d
    dcaf7
    Dec 30, 2021
    "Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the company has successfully completed its previously announced acquisition of Lengo Therapeutics and lead compound LNG-451, a potential best-in-class oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC) in patients with EGFR exon 20 insertion mutations. An investigational new drug (IND) application for LNG-451 was submitted to the U.S. Food and Drug Administration (FDA) by Lengo Therapeutics in December 2021.
    As previously disclosed, under the terms of the agreement, Blueprint Medicines acquired Lengo Therapeutics for $250 million in cash plus up to $215 million in additional potential payments based on the achievement of certain regulatory approval and sales-based milestones."
    It is how much cost EGFR Ex20ins TKI with zero clinical data. More than current M cap of Spectrum which has HER2 Ex20ins drug tested in more than 1000 patients and is ready for approval.
  • W
    Woody
    In the agreement, Hamni gets a seat on Spectrum’s board as long as they have at least 5% common stick shares.
  • C
    Chari
    There you go! Looking good!

    Spectrum Pharmaceuticals Announces New Strategic Investment by Hanmi Pharmaceutical
    9 minutes ago
    Business Wire
    Related Investments: Spectrum Pharmaceuticals Inc
    Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a $20 million equity investment by Hanmi Pharmaceutical along with revisions to the licensing agreements for ROLONTIS � and poziotinib. �This investment represents a strengthening in the relationship
  • j
    j
    If I'm reading this State Street filing correctly, they've sold a bunch of SPPI shares. Part of the reason for the extended drop?
    https://www.sec.gov/Archives/edgar/data/831547/000009375122000007/0000093751-22-000007-index.htm
    EDGAR Filing Documents for 0000093751-22-000007
    www.sec.gov